Settings

N = 396

%

M ± ET

Socio-demographic

Age (years)

57.4 ± 16.4

Sex (M)

235

59.3

Employment status

Active

225

56.8

Retired

107

27

Clinical (mode of decompensation)

Global HF

245

61.9

Right HF

91

23

Left HF

58

14.8

OAP

23

5.8

Cardiogenic shock

7

1.8

Echocardiography

LVDTD (mm)

60 ± 28.3

DTD ≥ 56 mm

176

55

LVEF< 45%.

236

60.4

Underlying heart disease

Dilated cardiomyopathy

143

36.1

Hypertensive cardiomyopathy

86

21.7

Ischemic cardiomyopathy

64

16.2

Valvulopathies

39

9.8

Pulmonary arterial hypertension

24

6.1

Peripartum cardiomyopathy

17

4.3

Pericarditis

15

3.8

Others

8

2

Treatment

Furosemide

361

91.2

Mineralocorticoid receptor antagonists (MRAs)

46

11.6

Beta-blockers

183

46.2

Angiotensin-converting enzyme inhibitors (ACEI)

288

72.7

Angiotensin receptor blockers (ARBs)

34

8.6

Others therapies

Calcium Channel blockers (CCBs)

28

7.1

Anticoagulants

36

9.1

Nitro derivatives

90

22.7

Aspirin

102

25.8

Statins

75

18.9

Intra-hospital Outcome

Favourable

374

94.4

Complications

41

10.4

death

22

5.5